Nemaura Medical Inc. Stock

Equities

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 01:57:10 2024-05-03 pm EDT 5-day change 1st Jan Change
0.043 USD +11.70% Intraday chart for Nemaura Medical Inc. -20.66% -80.37%
Sales 2024 * 200K Sales 2025 * 1.4M Capitalization 1.55M
Net income 2024 * -9M Net income 2025 * -12M EV / Sales 2024 * 7.77 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.11 x
P/E ratio 2024 *
-0.12 x
P/E ratio 2025 *
-0.09 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day+11.70%
1 week-20.66%
Current month-28.21%
1 month-46.25%
3 months-52.22%
6 months-81.92%
Current year-80.37%
More quotes
1 week
0.03
Extreme 0.033
0.06
1 month
0.03
Extreme 0.033
0.10
Current year
0.03
Extreme 0.033
0.21
1 year
0.03
Extreme 0.033
1.25
3 years
0.03
Extreme 0.033
17.40
5 years
0.03
Extreme 0.033
17.40
10 years
0.03
Extreme 0.033
96.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-12-23
Chief Operating Officer 47 22-01-04
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Chief Executive Officer 50 13-12-23
More insiders
Date Price Change Volume
24-05-03 0.043 +11.70% 27 400
24-05-02 0.0385 -27.97% 219,822
24-05-01 0.0534 -10.77% 10,839
24-04-30 0.0599 +9.11% 6,405
24-04-29 0.0549 +1.29% 30,812

Delayed Quote OTC Markets, May 03, 2024 at 01:57 pm EDT

More quotes
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0385 USD
Average target price
1.5 USD
Spread / Average Target
+3,796.10%
Consensus